Latest News

Mutant-Allele Tumor Heterogeneity (MATH) in head, neck squamous cell carcinoma patients is effective marker, along with HPV status, of improved patient outcome

Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient?s HPV status provides an effective indicator of improved patient outcome, according to research.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • New therapeutic target may improve treatment for brain cancer

  • New compounds could offer therapy for multitude of diseases

  • Stem cells make similar decisions to humans

  • Why good solutions make us oblivious to better ones

  • When attention is a deficit: Sometimes a new strategy makes sense

  • Stereotypes lower math performance in women, but effects go unrecognized

  • For drivers with telescopic lenses, driving experience and training affect road test results

  • Will you ever pay off your student loan?

  • Public Health Responsibility Deal in UK unlikely to be an effective response to alcohol harms

  • Immunotherapy used to reduce memory problems with Alzheimer's disease

  •